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Abstract Bone morphogenetic proteins (BMPs) regulate many
processes in the embryo, including cell type speci¢cation, pat-
terning, apoptosis, and epithelial^mesenchymal interaction.
They also act in soft and hard tissues in adult life. Their signals
are transduced from the plasma membrane to the nucleus
through a limited number of Smad proteins. The list of Smad-
interacting proteins is however growing and it is clear that these
partners determine the outcome of the signal. We summarize the
present status in BMP/Smad signaling, with emphasis on re-
cently identi¢ed Smad partners and how these proteins may
cooperate in the regulation of the expression of BMP target
genes.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Bone morphogenetic proteins (BMPs) form a large sub-
group within the transforming growth factor-L (TGF-L) fam-
ily of growth and di¡erentiation regulatory polypeptides.
BMPs were originally identi¢ed as proteins capable of induc-
ing ectopic cartilage and bone upon non-systemic injection in
mammals [1]. Later, they were shown to be crucial regulators
of early embryogenesis and subsequent organogenesis, and
tissue homeostasis in the adult [2]. Like other members of
the TGF-L family, BMPs elicit their e¡ects through activation
of combinations of two type I and two type II serine/threo-
nine kinase receptors (Fig. 1). Type I receptors within such
complexes act downstream of type II receptors and determine
the speci¢city of the signal [3]. Three distinct type II receptors,
BMP type II (BMPRII) and activin type IIA and IIB recep-
tors (ActRIIA and ActRIIB), and three type I receptors (ac-
tivin receptor-like kinases (or ALKs) ALK2, ALK3/BmprIA
and ALK6/BmprIB) have been identi¢ed for ligands of the
BMP subgroup. ALK3 and ALK6 are activated by BMP2,
BMP4 and BMP7, whereas ALK2 binds BMP6 and BMP7
but neither BMP2 nor BMP4.
The type I receptors within the tetrameric receptor complex
initiate signal propagation by phosphorylation of the recep-
tor-activated Smads (R-Smads). In addition to the R-Smads,
two other types of Smad have been identi¢ed, the common
mediator Smads (co-Smads, Smad4, or Smad4K and 4L in
Xenopus laevis) and the inhibitory Smads (I-Smads, Smad6
and Smad7). BMP receptors activate Smad1, Smad5 and
Smad8 (named here BR-Smads), whereas Smad2 and Smad3
are phosphorylated by the activin or TGF-L receptors (AR-
Smads). Remarkably, ALK3 and ALK6 can activate all three
BR-Smads, but ALK2 only phosphorylates Smad1 and
Smad5 [4]. The BR-Smads can however also transduce
TGF-L signals from the ALK1 type I receptor (for TGF-L)
in endothelium and hematopoietic cells [5]. Similarly, Mu«ller-
ian inhibiting substance (MIS; or anti-Mu«llerian hormone,
AMH) acts through MISRII (AMHRII) with ALK1 or
ALK6 [6,7], and some BMP-like growth/di¡erentiation factors
(GDF5, 6 and 7) act through activated ALK6 [8]. For many
ligands (e.g. BMP10 and 11, GDF1), it is still unclear through
which receptors and R-Smads they signal, particularly in vivo.
Activated R-Smads assemble into heteromeric complexes
with Smad4 in the cytoplasm and these accumulate in the
nucleus (for recent insights into nucleocytoplasmic shuttling
of Smads, see [9]) where they participate directly in the mod-
ulation of gene expression (Fig. 1). They do this by binding to
DNA, interacting with DNA binding transcription factors,
recruiting co-repressors or co-activators to speci¢c promoters
or mobilizing components of the chromatin-modifying ma-
chinery, or a combination of these modes [10,11](Table 1).
BMPs (and TGF-Ls) also initiate other non-Smad intracellu-
lar pathways, e.g. they can activate Jun N-terminal kinase
(JNK), p38 kinase/Akt and PI3 kinase pathways, as well as
caspases [12^14]. These pathways will not be discussed here.
2. Present status
Only ¢ve R-Smads mediate the majority of the complex
responses elicited in di¡erent tissues by ligands of the TGF-
L family. Depending on the cellular context, i.e. the spatial
and temporal-speci¢c cytoplasmic partners of Smads and,
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likewise, nuclear transcription factors and cofactors, the tran-
scriptional outcome of Smad activation can be speci¢ed and/
or ¢ne-tuned. Di¡erences in stability of signaling components
and their subcellular localization may as well a¡ect the cellu-
lar response. In addition, the modulation of BMP bioavail-
ability by BMP antagonists, or a pseudoreceptor (BAMBI;
[15]) add to the attenuation or complete silencing of BMP
elicited responses [16].
Smad proteins have three domains, the N-terminal Mad
homology domain (MH1), a divergent proline-rich linker do-
main, and the C-terminal MH2 domain [13]. The MH2 do-
main, which is highly conserved among all Smads, is in
R-Smads involved in type I receptor recognition and becomes
directly phosphorylated in its C-terminal SSXS motif by type
I receptors. This domain is also required for Smad oligome-
rization and interaction with Smad4, and is shown to interact
with cytoplasmic adapters and nuclear transcription factors
(Table 1). The MH1 domain is conserved among R- and co-
Smads, binds to several cytoplasmic partners, and is required
for nuclear import of Smads through its N-terminally located
nuclear localization signal. The MH1 domain of some
R-Smads has been shown to bind to DNA and to interact
with several nuclear proteins (Table 1).
At present, about 65 AR-Smad-interacting proteins have
been described [17,18], whereas few partners for BR-Smads
are known (Table 1). The strikingly less charged surface of
the BR-Smad trimeric complexes, as compared to AR-Smad
trimers, has been proposed to render BR-Smads less e⁄cient
for interaction and therefore restrict the number of BR-Smad
partners [17]. In addition, the most extensively BR-Smad that
is being studied is Smad1, and not many of its partners have
been tested for their interaction with Smad5 or Smad8 and for
the biological consequences of this interaction.
3. Interaction of BR-Smads with proteins in the cytoplasm
Several accessory/sca¡olding proteins, like SARA (Smad
anchor for receptor activation), axin and disabled2 (Dab2),
Fig. 1. BMP and TGF-L signaling pathways mediated by BR-Smads. Ligand-induced heteromeric receptor complex formation and phosphory-
lation of the type I receptor lead to phosphorylation of R-Smads. Activated R-Smads form complexes with co-Smad and accumulate in the nu-
cleus, where they participate, together with transcription factors and co-regulators, in the transcriptional regulation of target genes. It is pecu-
liar that TGF-L binds in endothelium in the presence of TLRII to ALK5 as well as to ALK1. The former activates the classical TGF-L/AR-
Smad pathway, whereas ALK1 activates BR-Smads and transmits therefore BMP-like signals. Di¡erent levels of modulation of the BMP/BR-
Smad signaling cascade are indicated schematically, see for details Table 1 and text.
FEBS 27353 12-6-03 Cyaan Magenta Geel Zwart
A. Zwijsen et al./FEBS Letters 546 (2003) 133^139134
have been described to interact with non-activated AR-Smads,
bridge them with the receptor complex, and assist in AR-
Smad activation [19]. SARA can anchor AR-Smads through
cooperation with Hgs/Hrs (hepatic growth factor-regulated
tyrosine kinase substrate) and their FYVE domain to the in-
ner lea£et of the plasma membrane or to early endosomes.
SARA-like adapter proteins have not yet been reported in the
BMP cascade, but Hgs/Hrs likely interacts with Smad1 [20],
indicating that there may be shared mechanisms that organize
R-Smad signaling centers at the plasma membrane but also
link their activity to membrane tra⁄cking (endocytosis) and
to degradation. In addition, the interaction of ¢lamin (an
actin cross-linking factor and sca¡olding protein) with
Smad1 and Smad5 enhances their signaling presumably by
serving as a track for intracellular Smad movement [21].
The observation that Smad1 can directly interact, although
weaker than Smad3, with proteins involved in epithelial cell
polarity (like Erbin, Par3, Dishevelled-1 (Dvl1) ; [22]), suggests
a mean by which BMPs could alter cell polarity. Dvl1 is an
intracellular protein involved in Wnt signaling, and its inter-
action with Smads may provide another level of cross-talk
between Wnt and TGF-L signal transduction. Par3, originally
identi¢ed in Caenorhabditis elegans, is involved in partitioning
(cell polarity). Erbin is a protein that binds to the receptor
ErbB2 and to several proteins that are involved in cytoskele-
ton and desmosome formation. Erbin also suppresses the mi-
togen-activated protein kinase (MAPK) pathway [23]. All
three proteins contain at least one PDZ domain, which ap-
pears not to be involved in Smad binding, but they can pro-
vide a platform for assembly of multi-protein complexes that
are targeted to speci¢c subcellular locations. Interestingly,
also Smad4 and Smad7 interact with Erbin, Dvl1 and Par3.
It is not clear yet whether these proteins interact at endoge-
nous levels in a ligand-dependent manner and how these in-
teractions modulate signaling [22].
Additional cytoplasmic or shuttling BR-Smad-interacting
partners, mainly involved in the negative regulation of Smads,
are discussed further below.
4. BR-Smad-interacting activators in the nucleus
The direct role of Smads in gene transcription is dependent
on their physical interaction with other DNA binding tran-
scription factors [24] and/or interaction with proteins like the
general transcriptional co-activator CBP/p300 [25]. Smad4 is
accepted as an essential functional partner in Smad-regulated
transcription, and has been shown to interact with CBP/p300.
Since CBP/p300 has intrinsic histone acetyl transferase (HAT)
activity and participates in chromatin remodeling, the recruit-
ment of CBP/p300 into the DNA binding complexes of
Smad1 and Smad4 has been claimed as a critical step in
Smad-regulated gene activation. However, our current knowl-
edge of the molecular details of the recruitment of CBP/p300
and other transcriptional modulators by Smads is still very
limited.
The multifunctional multi-zinc ¢nger protein OAZ (Olf-1/
EBF-associated zinc ¢nger) functions in BMP signaling as a
regulator of Smad1-dependent Xvent target gene transcription
Table 1
BR-Smad-interacting proteins
Function MH1 domain Smad Linker domain Smad MH2 domain Smad
1 5 8 1 5 8 1 5 8
Receptors ALK1 F F F
ALK2 F F E
ALK3 F F F
ALK6 F F F
Oligomerization R-Smads, Co-Smad, I-Smads
Cytoplasmic adapters, e¡ectors calmodulin F ¢lamin F F SANE F F
¢lamin F F Hgs/Hrs 8 HsN3 F
HEF1 8 Smurf1 F F Az F
Erbin F Smurf2 F
Dvl1 F
Par3 F
Nuclear membrane proteins MAN1 F F F
Transcriptional regulators Hoxc8 F Gli3v-ter F BF-1 F 8
Vent2 F CIZ F F F
Znf8 F F Hoxc8 F E1A F F
JunB 8 8 Lef1/Tcf 8 F
menin F F OAZ F
Ngn F p300/CBP 8
Swift 8 Runx1/PebpKB/CBFA2/AML1 F F
Runx2/PebpKB/CBFA1/AML3 F F
Runx3/PebpKC/CBFA3/AML2 F F
c-Ski 8 8
SIP1 F F
SNIP1 8 E
TGIF 8
Tob F F F
Znf8 F F
Table of the BR-Smad protein^protein interactions known to occur in each domain. Entries in more than one domain indicate interactions
with the same factor at multiple domains. If the speci¢c Smad domain that interacts with the protein is not yet determined, the protein is indi-
cated in italic. The speci¢city of the interaction to Smad1, Smad5 or Smad8 is indicated by symbols: F : positive interaction, 8 : weak interac-
tion, E : no interaction, blank: not determined. Names and references of proteins not discussed in the text are: BF-1: brain factor 1 [64]; cal-
modulin [65]; E1A: early region [66]; Gliv-ter [67] ; HEF1: human enhancer of ¢lamentation [68]; JunB [69]; Lef1/Tcf: lymphoid enhancer
binding factor 1/T-cell factor [70]; Ngn1: neurogenin [71]; Swift [72].
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and acts, through other zinc ¢nger-rich domains, in a Smad-
independent fashion as an inhibitory partner of the Olf-1/EBF
bHLH activator in pre-B-lymphocytes and olfactory epitheli-
um. OAZ may in fact provide three levels of speci¢city in
BMP signaling. It is able to cooperate with Smad1 and not
with Smad2. OAZ seems to provide target gene speci¢city in
BMP-stimulated cells, because it recognizes target genes that
contain appropriate BMP response elements (BRE) (the 3P-
£anking box in the Xvent2 gene) but not other genes such as
Tlx2. Finally, by being expressed in some cell types only,
OAZ provides cell-type speci¢city to the response of OAZ-
dependent BMP target genes [26].
Genes of the Xvent family of homeodomain-containing
transcription factors, like Xvent2, are not only immediate
response genes to BMP4 signaling in the ventral mesoderm
of the Xenopus embryo. A recent study identi¢ed Xvent2 as a
Smad1 binding protein, and provided evidence that Xvent2
maintains and/or ampli¢es its own expression by binding to
its own promoter, and autoregulates its own transcription and
in a Smad-dependent fashion [27].
BR-Smads have been documented to interact, in contrast to
AR-Smads, only with a limited number of transcription fac-
tors, including the family with a Runt domain (Runx1 to 3)
that are integral components of AR- and BR-Smad signaling
cascades in hematopoiesis and in osteogenesis [28]. The inter-
action of Runx2 with Smad1 or Smad5 enhances the osteo-
genic actions of Runx2 signi¢cantly, and its expression is de-
pendent on Smad1/Smad5 activation [29] (Table 2).
The tumor suppressor menin interacts with Smad3 and
many transcription factors, shuttles between cytoplasm and
nucleus, and is likely involved in cell cycle regulation, and
DNA repair or synthesis [30]. Recently, the functional inter-
action of menin with Smad1 and Smad5 was documented [31].
Knockdown studies in C3H10T1/2 cells revealed interestingly
that menin did not a¡ect BMP2-induced chondrogenesis and
adipogenesis but is required for ligand-induced commitment
into the osteoblast lineage, and early di¡erentiation of osteo-
blasts.
5. BR-Smad-interacting repressors in the nucleus
Several nuclear proteins have been implicated in transcrip-
tional repression of TGF-L/BMP target genes. The homeodo-
main protein TGIF and the c-Ski protein were identi¢ed as
transcriptional co-repressors of Smad2 and Smad3 in a TGF-
L-dependent manner [32], but they interact only weakly with
BR-Smads. The protein Tob, on the other hand, interacts
speci¢cally with Smad1, Smad5 and Smad8, as well as with
Smad4, recruits them to nuclear bodies, and represses BMP-
induced and Smad-dependent transcription in osteoblasts [33].
Smad1 interacts also with Hoxc8, a homeodomain tran-
scriptional repressor, and dislodges Hoxc8 from its DNA
binding element, resulting in the induction of speci¢c BMP
target genes [34,35]. Smad-interacting protein-1 (SIP1), a
member of the Zfhx family, is a multi-zinc ¢nger DNA bind-
ing protein that acts as a repressor of a number of promoters
of embryonically relevant genes [36]. A novel Kru«ppel-type
zinc ¢nger protein, mZnf8, endogenously interacts with
R- and co-Smads, and shows highest a⁄nity for Smad1/5 [37].
Like many other Kru«ppel-type zinc ¢nger proteins, Znf8 ap-
pears as a transcriptional repressor of BMP and to a lesser
extent TGF-L reporter genes. In addition, knockdown of en-
dogenous Znf8 revealed its function in selective repression of
certain BMP reporter genes (e.g. 12xGCGC based) and not of
other reporter genes (e.g. Tlx2 based). At present, di¡erent
modes of action of Znf8 may be envisaged. First, like
Hoxc8 and as proposed for Brinker in Drosophila, Znf8 may
function as a transcriptional repressor of speci¢c BMP target
genes. Binding of activated Smad to Znf8 could dislodge it
from its binding site, allowing the transcription of target
genes. This is however unlikely because knockdown of Znf8
should then result in BMP-independent induction of target
genes, which was not seen. Alternatively, Znf8 may rather
serve as a general inhibitor that blocks the activity of Smad
proteins. A similar mechanism was proposed for Smad nu-
clear interacting protein-1 (SNIP1, [38]). Znf8 may also take
part in a transcriptional co-repressor complex with Smads to
repress target genes, similar to Ski and TGIF for AR-Smads.
It is particularly interesting that Znf8 can interact, unlike the
other Smad-interacting co-repressors, with both the MH1 and
MH2 domain of Smad1. Consequently, the inhibition of
Smad1 activity by Znf8 may have two e¡ects by blocking
the Smad1 DNA binding activity through interaction with
the MH1 domain and by blocking Smad1 trans-activation
Table 2
Selection of BMP/BR-Smad target genes
Target gene Function Reference
BIG-3 seven WD-40 repeat protein [73]
BIKe Ser/Thr protein kinase [74]
Runx2/cbfa1/OSF2 DNA binding subunit of core binding transcription factor CBP [29]
Dlx-2, Dlx-3, Dlx-5 homeobox proteins [75^77]
GATA2, GATA4 zinc ¢nger transcription factors [78^81]
Hex homeobox protein [82]
Id1, Id2, Id3 inhibitors of basic helix-loop-helix proteins [83]
JunB proto-oncogene [84]
Msx-1 homeobox protein [83]
Msx-2 homeobox protein [83]
Nkx2.5 homeobox protein [50,51]
Noggin BMP antagonist [85]
Osteopontin (OPN) bone matrix protein [86]
Osteoprotegrin (OPG) soluble decoy TNF receptor [87]
Smad6 inhibitory Smad [47]
Smad7 inhibitory Smad [45]
Tbx2 T-box transcription factor [88]
Tlx-2 homeobox protein [89,90]
Vent2 homeodomain transcription factor [46]
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activity through binding to the MH2 domain. Znf8 could set
thresholds for BMP signaling due to the di¡erent a⁄nity of
Znf8 for di¡erent Smads, providing a new mechanism for cells
to have di¡erent sensitivities to di¡erent ligands [37].
The Cas-interacting zinc ¢nger protein (CIZ) has recently
been described as a negative regulator in BMP/Smad signaling
[39], known as nucleocytoplasmic shuttling protein, which lo-
calized in focal adhesions and nuclei, and was suggested to
function in cell attachment and concomitant gene expression.
A novel ¢nding is that di¡erentiation of osteoblasts turns out
to be suppressed by CIZ through interaction with BR-Smads.
The inner nuclear membrane protein MAN1 is a new and
recent player in the ¢eld. MAN1 speci¢cally interacts with the
MH2 domain of BR-Smads and antagonizes BMP e¡ects in
Xenopus embryos by suppression of known target genes for
BMPs, thereby acting as a neuralizing factor [40]. Inner nu-
clear membrane proteins have been implicated mainly in dis-
assembly and subsequent reassembly of the nuclear envelope
in mitosis, based on their proximity to the nuclear lamina and
chromatin. The molecular action mechanism of MAN1 in
BR-Smad signaling is unknown, but MAN1 may titrate out
BR-Smads and prevent their association with other transcrip-
tion regulators, or alternatively it may recruit a co-repressor
on the MH2 domain as has been suggested for the c-Ski
oncoprotein [41].
6. Smad4-interacting factors involved in BMP signaling
Although emphasis here is not on Smad4-interacting pro-
teins involved in BMP signaling, they represent yet another
mechanism to modulate BMP and TGF-L signaling. For ex-
ample, SMIF is a Smad4-interacting protein that does not
display sequence similarities with known functional domains,
including those that bind DNA [42]. The SMIF/Smad4 inter-
action is BMP and TGF-L dependent, and the complex trans-
locates to the nucleus upon ligand stimulation. SMIF appears
as a transcriptional co-activator in Smad4 containing tran-
scriptional complexes, essential for a subset of BMP-induced
cellular responses [43].
Msx1 is a target gene and mediator of BMP signaling.
Recent data indicate that Msx1 can bind to Smad1 or 2 as
well as Smad4K or L in Xenopus. Dependent on the presence
of Smad4, Msx1 can exclude FAST proteins from Smad2/4
complexes and has been proposed to antagonize nodal signal-
ing [44].
7. Target genes
Although many BMP-induced genes are documented, in-
cluding Msx, Id genes (inhibitor of di¡erentiation) Id1 to 3,
Smad6, Vent2 and Tlx2 (Table 2), relatively few genes have
been identi¢ed as BR-Smad target genes (Table 3). Some BR-
Smad target genes encode BR-Smad-interacting proteins and
are involved in the induction of autoregulatory (Vent2) or
negative feedback (Smad6, Tob) loops in BMP signaling, as
well as the induction of indirect BMP target genes (e.g. Oste-
rix, EKLF, Collagen 2a1).
The responsive regions of TGF-L/activin target genes con-
tain Smad binding elements (SBEs), consisting of a consensus
sequence of CAGAC, or minimally AGAC [32]. But Smad
binding to these SBEs is fairly weak and lacks selectivity,
therefore requiring additional DNA binding factors for high
a⁄nity, speci¢c recruitment of the Smad complex to a distinct
target promoter, a mechanism likely to be conserved in both
BMP and TGF-L signaling cascades. BR-Smads (e.g. Smad7
promoter), and Smad3 and Smad4 (e.g. PAI-1 promoter) can
bind SBE CAGAC sequences, likely depending on the £ank-
ing sequences. Remarkably, though Smad5 falls in the same
family of BR-Smads as Smad1 and Smad8, Smad5 has DNA
SBE binding properties similar to Smad3 in the Smad7 pro-
moter, a feature not shared by Smad1 and Smad8 [45].
BR-Smads have been shown to weakly bind GCAT or
GCCG motifs, so-called BREs found in BMP target genes
like Xvent2 and Smad6 [46,47]. However, BMP inducibility
of multimerized GC-rich reporter constructs is very low and
requires R-Smad overexpression.
Id proteins play important roles in the multiple biological
functions of BMPs as they act as negative regulators of cell
di¡erentiation and positive mediators of cell proliferation [48].
Id proteins sequester ubiquitous bHLH transcription factors
and inhibit their transcriptional activities. The Id1 promoter
contains several BMP-responsive regions that contain SBEs
and CAGC and CGCC motifs [49]. Nearly identical CGCC
BREs are retrieved in the BMP-responsive Hex and Nkx2.5
promoters [50,51].
Recently, di¡erent gene expression pro¢ling analyses have
yielded novel BMP target genes involved in osteoblast di¡er-
entiation of C2C12 mesenchymal progenitor cells [52^54] and
in ALK1/Smad5-mediated TGF-L signaling in endothelium
[55]. These approaches will continue to give further insight
in BR-Smad transcriptional cascades and lead to the identi-
¢cation of their direct target genes.
8. Further modulation of Smad-mediated BMP signaling by
BR-Smad-interacting proteins
Smad6 blocks predominantly the BMP pathway by compet-
ing with Smad4 for binding to activated Smads [56], and
Table 3
BR-SBE
Gene BRE Mechanism Reference
Dlx-3 GCAT motif Smad1/Smad4 binding [76]
Hex 2x GCCGnCGC Smad1/Smad4 binding [82]
2x CAGAC (SBE) Smad4 binding
Id1 2U SBE, GGCGCC, CAGC and CGCC Smad5/Smad4 binding [49]
Nkx2.5 multiple GTCT/AGAC, GCCGCGC Smda4 binding, Smad1/5/Smad4 binding [50,51]
Osteopontin AGACTGTCTGGAC Smad1/Smad4 dislodges Hoxc8 from its HRE [86]
Smad6 GCCGCGCC motif Smad1/4 [47]
Smad7 SBE GTCTAGAC Smad2/3/5-speci¢c, no Smad1/8 binding [45]
Vent2B GCAT motif (Smad1) Smad1/5 and OAZ [26,46]
AGNC motif (Smad4)
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Smad7 inhibits phosphorylation of Smad1 by interacting with
activated BMP type I receptors [57]. Smad6, but not Smad7,
interacts with both Hoxc8 and Hoxa9 proteins as a hetero-
dimer when binding to DNA. The Smad6^Hoxc8 complex
inhibits interaction of Smad1 with Hoxc8 and, consequently,
Smad1-induced transcription. These data suggest that Smad6
interacts with Hox proteins as part of a negative feedback
circuit for modulating the magnitude and duration of BMP
signaling [43].
Recently, SANE (Smad1 antagonistic e¡ector) was identi-
¢ed [58] and shown to interact speci¢cally with the MH2
domain of BR-Smads and BMP type I receptors (i.e. ALK3
and 6, but not ALK2). The interaction with both a receptor
and R-Smad makes it resemble SARA. However, SANE ap-
pears to antagonize BMP signaling in Xenopus embryos and
mammalian cells by inhibiting BR-Smad phosphorylation and
blocking nuclear translocation. This protein may represent a
new mode of regulation for intracellular BMP signaling. It
shows no sequence similarity to other proteins that interact
with BR-Smads and/or BMP receptors, with the notable ex-
ception of MAN1. The highest sequence similarity is found in
the carboxy-terminal region, which includes the Smad binding
domain of SANE.
Smad-dependent proteasome-mediated degradation of
Smads themselves but also of cytoplasmic and nuclear Smad
partners is an important aspect of TGF-L/BMP signaling as
well. Smurf1 and Smurf2, which are Hect E3 ubiquitin ligases,
selectively interact with BR-Smads (although Smurf2 has also
a⁄nity for Smad2) to trigger their ubiquitination and subse-
quent degradation, and hence their inactivation [59,60].
Smurf1 interacts also with Smad7, which is exported from
the nucleus in ligand-treated cells, and induces Smad7 ubiq-
uitination. In addition, Smurf1 associates with ALK5 (TLRI)
via Smad7, with subsequent enhancement of TLRI and Smad7
turnover [61]. Ubiquitination, however, is not an obligate step
for substrate targeting to the proteasome. Recently, Smad1
was shown to interact with two proteins that function along
the degradation pathway of the 26S proteasome, i.e. antizyme
(Az) and HsN3 [62,63]. Activation of BMP type I receptor
triggers binding of Smad1 to Az and HsN3, and brings them ^
likely with Smad4 ^ into the nucleus, where the CBP/p300
repressor SNIP1 is recruited to the complex and co-targeted
to the proteasome. Smad4 seems a positive regulator of tar-
geting SNIP1 to the proteasome. SNIP1 is a potent inhibitor
of Smad-responsive genes in BMP pathways via inhibiting
CBP/p300. The degradation of SNIP1 may be an essential
step for Smad1/Smad4-mediated transcriptional activation,
since an increase of SNIP1 expression inhibits BMP-induced
gene responses [63].
9. Conclusions
The true web of Smad interactions that is triggered when
cells perceive a BMP stimulus, and the adequate integration
into an appropriate transcriptional modulation of gene ex-
pression, is still of a higher order than we can currently re-
view, as aspects of concentration and subcellular localization
of Smad partners become critical parameters. Much from the
future identi¢cation of more components of the BMP path-
way and from our insight in the endogenous/physiological
interplay between signaling components is likely to come
from studies involving knockout and knockdown approaches
in entire embryos (or tissues thereof) and in cell cultures spe-
ci¢cally designed for this purpose. In addition, TGF-L ligands
function in complex growth factor/cytokine environments,
and it is anticipated that many studies will have to address
the complexity of cross-talk of their signal transduction with
the Smad pathway.
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